Seattle Genetics Inc (NASDAQ:SGEN) Institutional Investors Sentiment Index Improved in Q4 2016

July 17, 2017 - By Nellie Frank

 Seattle Genetics Inc (NASDAQ:SGEN) Institutional Investors Sentiment Index  Improved in  Q4 2016

Sentiment for Seattle Genetics Inc (NASDAQ:SGEN)

Seattle Genetics Inc (NASDAQ:SGEN) institutional sentiment increased to 1.2 in Q4 2016. Its up 0.20, from 1 in 2016Q3. The ratio has increased, as 124 active investment managers started new and increased equity positions, while 103 reduced and sold stakes in Seattle Genetics Inc. The active investment managers in our partner’s database now have: 135.77 million shares, down from 137.16 million shares in 2016Q3. Also, the number of active investment managers holding Seattle Genetics Inc in their top 10 equity positions decreased from 6 to 5 for a decrease of 1. Sold All: 30 Reduced: 73 Increased: 64 New Position: 60.

Seattle Genetics, Inc. is a biotechnology firm focused on the development and commercialization of therapies for the treatment of cancer. The company has market cap of $7.65 billion. The Firm is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. It currently has negative earnings. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate .

About 347,053 shares traded. Seattle Genetics, Inc. (NASDAQ:SGEN) has risen 75.68% since July 17, 2016 and is uptrending. It has outperformed by 58.98% the S&P500.

Analysts await Seattle Genetics, Inc. (NASDAQ:SGEN) to report earnings on July, 25. They expect $-0.44 earnings per share, down 91.30 % or $0.21 from last year’s $-0.23 per share. After $-0.42 actual earnings per share reported by Seattle Genetics, Inc. for the previous quarter, Wall Street now forecasts 4.76 % negative EPS growth.

Baker Bros. Advisors Lp holds 23.65% of its portfolio in Seattle Genetics, Inc. for 45.71 million shares. Lagoda Investment Management L.P. owns 517,829 shares or 9.38% of their US portfolio. Moreover, Redmile Group Llc has 6.92% invested in the company for 1.52 million shares. The California-based Venbio Select Advisor Llc has invested 3.15% in the stock. Opus Point Partners Management Llc, a New York-based fund reported 68,310 shares.#img1#

Since January 1, 0001, it had 0 buys, and 7 selling transactions for $5.61 million activity.

Seattle Genetics, Inc. (NASDAQ:SGEN) Ratings Coverage

Ratings analysis reveals 40% of Seattle Genetics’s analysts are positive. Out of 15 Wall Street analysts rating Seattle Genetics, 6 give it “Buy”, 1 “Sell” rating, while 8 recommend “Hold”. The lowest target is $4300 while the high is $7500. The stock’s average target of $59.40 is 10.12% above today’s ($53.94) share price. SGEN was included in 33 notes of analysts from July 31, 2015. The rating was maintained by Jefferies on Monday, June 12 with “Buy”. Cowen & Co maintained Seattle Genetics, Inc. (NASDAQ:SGEN) on Tuesday, June 6 with “Hold” rating. The company was maintained on Wednesday, July 27 by Barclays Capital. Cowen & Co maintained it with “Hold” rating and $5400 target in Monday, June 26 report. The firm has “Hold” rating given on Monday, June 26 by Cantor Fitzgerald. The firm has “Hold” rating by Cantor Fitzgerald given on Monday, June 19. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) has “Equal-Weight” rating given on Tuesday, November 29 by Barclays Capital. The stock has “Hold” rating by Oppenheimer on Monday, June 26. On Friday, June 2 the stock rating was maintained by Oppenheimer with “Hold”. The firm has “Underperform” rating given on Friday, February 10 by Bank of America.

More notable recent Seattle Genetics, Inc. (NASDAQ:SGEN) news were published by: which released: “Seattle Genetics Enters Oversold Territory (SGEN)” on June 26, 2017, also with their article: “Seattle Genetics suspends trial of leukemia treatment after data showed higher …” published on June 19, 2017, published: “The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle …” on July 14, 2017. More interesting news about Seattle Genetics, Inc. (NASDAQ:SGEN) were released by: and their article: “Why Shares of Seattle Genetics, Inc. Got Whacked Today” published on June 26, 2017 as well as‘s news article titled: “BUZZ-US STOCKS ON THE MOVE-Micron, Sorrento, Seattle Genetics, Pandora …” with publication date: June 26, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.